Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,438 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 669 · Balance 7,438 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Child 1 | 0 |
Reported balance
After 2025-02-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 2 | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 3 | 0 |
Reported balance
After 2025-02-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-02-19 · Other · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-19 transaction · row 6
2 source rows · reconciled sequenceRow 5 · 2025-02-19 · Grant · Acquired 20,393 · Balance 717,637 F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. Row 6 · 2025-02-19 · Other · Disposed 717,637 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.00 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-19 · Disposition to issuer · Disposed 36,085 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.44 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Disposition to issuer · Disposed 44,693 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance.
F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:46 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 669 | $19.60 | $13,112.40 |
DisclosureSEC source: 0001806431-26-000005 · wk-form4_1791319594.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,438 F1 · shares: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 21:07 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 5,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001806431-26-000004 · wk-form4_1782767226.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,769 F1 · shares: Represents an award of restricted stock units ("RSUs"). The RSUs will vest on the earlier of the date of the annual meeting of stockholders to be held in 2027 or June 26, 2027. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. F2 · balance_after: Includes 1,723 shares received without consideration as an in-kind distribution from Gilmartin Capital Fund I, LP. In prior reports, the Reporting Person reported no beneficial ownership of Shoulder Innovations Common Stock. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Disposition to issuerStock Options (Right to Buy) · Derivative | 44,693 | Not disclosed Strike: $58.44 | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · derivative · entry 8 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,693 shares Expires not disclosed F4 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F4 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F4 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Disposition to issuerStock Options (Right to Buy) · Derivative | 36,085 | Not disclosed Strike: $56.00 | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · derivative · entry 7 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,085 shares Expires not disclosed F4 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F4 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F4 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 717,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F3 · shares: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 20,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 717,637 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. F2 · shares: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 1,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Child 3 Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 1,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Child 2 Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 1,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005734 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Child 1 Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Option · Derivative | 16,719 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-25-004391 · form4.xml · derivative · entry 10 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,719 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became fully vested and exercisable as of January 1, 2023. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Option · Derivative | 16,719 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001127602-25-004391 · form4.xml · derivative · entry 9 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,719 shares Expires 2030-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became fully vested and exercisable as of January 1, 2024. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 161,100 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001127602-25-004391 · form4.xml · derivative · entry 8 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 161,100 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became fully vested and exercisable as of March 29, 2022. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 16,719 | $0.46 | $7,638.91 |
DisclosureSEC source: 0001127602-25-004391 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 16,719 | $6.45 | $107,914.46 |
DisclosureSEC source: 0001127602-25-004391 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:42 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 161,100 | $0.43 | $69,015.24 |
DisclosureSEC source: 0001127602-25-004391 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 663,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:47 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 67,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003433 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,706 F1 · shares: Represents restricted stock units ("RSUs") awarded to the reporting person, with a vesting commencement date of January 1, 2025 (the "Vesting Commencement Date"). 1/16th of the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. F2 · balance_after: Includes 523 shares acquired on January 31, 2025, under the Company's Employee Stock Purchase Plan. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:51 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,319 | $51.05 | $67,334.95 |
DisclosureSEC source: 0001127602-25-000485 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,901 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:51 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,632 | $51.05 | $83,313.60 |
DisclosureSEC source: 0001127602-25-000485 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,220 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:51 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 949 | $51.05 | $48,446.45 |
DisclosureSEC source: 0001127602-25-000485 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,852 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:51 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 509 | $51.05 | $25,984.45 |
DisclosureSEC source: 0001127602-25-000485 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,801 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| December 20, 2024 Filed Dec 21, 2024 00:18 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $55.65 | $33,390.00 |
DisclosureSEC source: 0001127602-24-029927 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,310 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $55.56 to $55.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 20, 2024 Filed Dec 21, 2024 00:18 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,400 | $55.20 | $132,480.00 |
DisclosureSEC source: 0001127602-24-029927 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,910 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.56 to $55.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,000 | $50.83 | $152,490.00 |
DisclosureSEC source: 0001127602-24-027912 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,310 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,000 | $50.00 | $150,000.00 |
DisclosureSEC source: 0001127602-24-026168 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 445,310 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:36 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,292 | $40.63 | $52,493.96 |
DisclosureSEC source: 0001127602-24-025128 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,310 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:36 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,475 | $40.63 | $59,929.25 |
DisclosureSEC source: 0001127602-24-025128 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,602 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:36 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 947 | $40.63 | $38,476.61 |
DisclosureSEC source: 0001127602-24-025128 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,077 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:36 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 508 | $40.63 | $20,640.04 |
DisclosureSEC source: 0001127602-24-025128 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,024 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:34 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,000 | $50.00 | $150,000.00 |
DisclosureSEC source: 0001127602-24-022796 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,532 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F2 · balance_after: Includes 280 shares acquired on July 31, 2024 through the Issuer's Employee Stock Purchase Program. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 21:04 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,000 | $55.23 | $165,690.00 |
DisclosureSEC source: 0001127602-24-020966 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,252 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.92 to $55.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:04 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,292 | $50.19 | $64,845.48 |
DisclosureSEC source: 0001127602-24-020038 · form4.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,252 F6 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:04 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,475 | $50.19 | $74,030.25 |
DisclosureSEC source: 0001127602-24-020038 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,544 F5 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:04 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 947 | $50.19 | $47,529.93 |
DisclosureSEC source: 0001127602-24-020038 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,019 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:04 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 508 | $50.19 | $25,496.52 |
DisclosureSEC source: 0001127602-24-020038 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,966 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:04 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,000 | $50.08 | $150,240.00 |
DisclosureSEC source: 0001127602-24-020038 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,474 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:14 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,000 | $50.00 | $150,000.00 |
DisclosureSEC source: 0001127602-24-017012 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,474 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012247 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,474 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012247 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,766 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012247 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,241 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 508 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012247 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,188 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:52 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantStock Options (Right to Buy) · Derivative | 44,693 | $58.44 Strike: $58.44 | $2,611,858.92 |
DisclosureSEC source: 0001127602-24-006227 · form4.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,693 Underlying: Common Stock · 44,693 shares Expires 2031-02-15 F3 · derivative.exercise_date: Represents options to purchase shares of Issuer common stock which were granted on February 16, 2024 under the Issuer's 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis, with the first tranche vesting on April 1, 2024. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:52 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 40,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006227 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,696 F1 · shares: Represents annual restricted stock units ("RSUs") awarded to the reporting person, with a vesting commencement date of January 1, 2024 (the "Vesting Commencement Date"). 1/16th of the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. F2 · balance_after: Includes 156 shares acquired on January 31, 2024, under the Company's Employee Stock Purchase Plan. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,610 | $64.92 | $104,521.20 |
DisclosureSEC source: 0001127602-24-000288 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,754 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 945 | $64.92 | $61,349.40 |
DisclosureSEC source: 0001127602-24-000288 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 433,364 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 508 | $64.92 | $32,979.36 |
DisclosureSEC source: 0001127602-24-000288 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,309 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| November 16, 2023 Filed Nov 18, 2023 00:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 16,415 | $60.20 | $988,183.00 |
DisclosureSEC source: 0001127602-23-027915 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,817 F1 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.93 to $60.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2023 Filed Nov 18, 2023 00:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 21,033 | $59.53 | $1,252,094.49 |
DisclosureSEC source: 0001127602-23-027915 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,232 F1 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.93 to $59.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2023 Filed Oct 4, 2023 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,443 | $65.40 | $94,372.20 |
DisclosureSEC source: 0001127602-23-025402 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,265 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| October 01, 2023 Filed Oct 4, 2023 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 927 | $65.40 | $60,625.80 |
DisclosureSEC source: 0001127602-23-025402 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,708 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.